MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis
Metrics: PDF 453 views | HTML 921 views | ?
Xing Huang1,*, Qi Sun2,*, Chen Chen3,*, Yi Zhang1, Xin Kang4, Jing-Yuan Zhang1, Da-Wei Ma1, Lei Xia1, Lin Xu5, Xin-Yu Xu1 and Bin-Hui Ren5
1Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China
2Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu, China
3Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China
4Department of General Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
5Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China
*These authors contributed equally to this work
Xin-Yu Xu, email: email@example.com
Bin-Hui Ren, email: firstname.lastname@example.org
Keywords: mucin1, biomarker, NSCLC, prognosis, meta-analysis
Received: February 28, 2017 Accepted: July 18, 2017 Published: August 03, 2017
Background: Previous studies on the prognostic role of MUC1 expression in non-small cell lung cancer (NSCLC) remain controversial. We conducted a meta-analysis to appraise the clinicopathological and prognostic effect of MUC1 in NSCLC patients.
Materials and Methods: Searches of PubMed, EMBASE and CNKI (Chinese National Knowledge Infrastructure) were conducted and relevant studies were extracted. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (CIs) were used to estimate effects. Heterogeneity among studies and publication bias were also evaluated.
Results: A total of 15 studies with 1,682 patients were included in this meta-analysis. The pooled HRs indicated that elevated MUC1 expression was associated with poorer overall survival (HR = 2.12, 95% CI: 1.47–3.05; P < 0.001) and progression-free survival (HR = 2.00, 95% CI: 1.53-2.62; P < 0.001) in patients with NSCLC. Significant associations were also found in patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (HR = 3.16, 95% CI: 2.21–4.52, P < 0.001) and with a platinum-based regimen (HR = 4.35, 95% CI: 2.45–7.72, P < 0.001). Additionally, MUC1 overexpression was significantly associated with performance status (OR = 2.32, 95% CI: 1.13–4.73, P = 0.021).
Conclusions: MUC1 could be a valuable biomarker of the prognoses of NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.